Table 23-4.

Time Trends in GWTG-HF Quality-of-Care Measures, 2006 to 2014

Quality-of-Care Measure200620072008200920102011201220132014
LVEF assessment*93.595.596.498.098.096.696.599.099.0
ARB/ACEI at discharge for patients with LVSD*85.489.191.592.994.295.295.495.695.3
Postdischarge appointment (new for 2011)*16.347.461.367.7
Complete discharge instructions91.094.997.297.799.393.893.494.195.7
Evidence-based specific β-blockers*67.758.954.145.248.457.182.686.691.1
β-Blockers at discharge for patients with LVSD, no contraindications90.090.492.692.594.896.097.297.797.9
Anticoagulation for AF or atrial flutter, no contraindications62.361.260.568.870.275.978.780.182.2
  • Values are percentages. ACEI indicates angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; ARB, angiotensin receptor blocker; GWTG-HF, Get With The Guidelines–Heart Failure; LVEF, left ventricular ejection fraction; and LVSD, left ventricular systolic dysfunction.

  • * Indicates the 4 key achievement measures targeted in GWTG-HF. The composite quality-of-care measure for 2014 was 96.9%. The composite quality-of-care measure indicates performance on the provision of several elements of care. It is computed by summing the numerators for each key achievement measure across the population of interest to create a composite numerator (all the care that was given), summing the denominators for each measure to form a composite denominator (all the care that should have been given), and reporting the ratio (the percentage of all the needed care that was given). The composite performance measure includes β-blocker at discharge instead of evidence-based specific β-blockers and complete discharge instructions instead of postdischarge appointment until the data collection for the new achievement measures stabilizes.